116 related articles for article (PubMed ID: 26025930)
1. MDM2 mediates p73 ubiquitination: a new molecular mechanism for suppression of p73 function.
Wu H; Leng RP
Oncotarget; 2015 Aug; 6(25):21479-92. PubMed ID: 26025930
[TBL] [Abstract][Full Text] [Related]
2. MDM2 suppresses p73 function without promoting p73 degradation.
Zeng X; Chen L; Jost CA; Maya R; Keller D; Wang X; Kaelin WG; Oren M; Chen J; Lu H
Mol Cell Biol; 1999 May; 19(5):3257-66. PubMed ID: 10207051
[TBL] [Abstract][Full Text] [Related]
3. Functional interplay between MDM2, p63/p73 and mutant p53.
Stindt MH; Muller PA; Ludwig RL; Kehrloesser S; Dötsch V; Vousden KH
Oncogene; 2015 Aug; 34(33):4300-10. PubMed ID: 25417702
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the Mdm2-p53 pathway by the ubiquitin E3 ligase MARCH7.
Zhao K; Yang Y; Zhang G; Wang C; Wang D; Wu M; Mei Y
EMBO Rep; 2018 Feb; 19(2):305-319. PubMed ID: 29295817
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2.
Wiech M; Olszewski MB; Tracz-Gaszewska Z; Wawrzynow B; Zylicz M; Zylicz A
PLoS One; 2012; 7(12):e51426. PubMed ID: 23251530
[TBL] [Abstract][Full Text] [Related]
6. Loss of Expression of Reprimo, a p53-induced Cell Cycle Arrest Gene, Correlates with Invasive Stage of Tumor Progression and p73 Expression in Gastric Cancer.
Saavedra K; Valbuena J; Olivares W; Marchant MJ; Rodríguez A; Torres-Estay V; Carrasco-Avino G; Guzmán L; Aguayo F; Roa JC; Corvalán AH
PLoS One; 2015; 10(5):e0125834. PubMed ID: 25954972
[TBL] [Abstract][Full Text] [Related]
7. The RNA binding protein RALY suppresses p53 activity and promotes lung tumorigenesis.
Hu H; Zhao K; Fang D; Wang Z; Yu N; Yao B; Liu K; Wang F; Mei Y
Cell Rep; 2023 Apr; 42(4):112288. PubMed ID: 36952348
[TBL] [Abstract][Full Text] [Related]
8. The antiapoptotic DeltaNp73 is degraded in a c-Jun-dependent manner upon genotoxic stress through the antizyme-mediated pathway.
Dulloo I; Gopalan G; Melino G; Sabapathy K
Proc Natl Acad Sci U S A; 2010 Mar; 107(11):4902-7. PubMed ID: 20185758
[TBL] [Abstract][Full Text] [Related]
9. LncRNA NRON promotes tumorigenesis by enhancing MDM2 activity toward tumor suppressor substrates.
Guo Q; Li Y; Zhang Y; Shen L; Lin H; Chen J; Song E; Luo ML
EMBO J; 2023 Aug; 42(16):e112414. PubMed ID: 37382239
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway.
Bang S; Kaur S; Kurokawa M
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905981
[TBL] [Abstract][Full Text] [Related]
11. Measles virus V protein inhibits p53 family member p73.
Cruz CD; Palosaari H; Parisien JP; Devaux P; Cattaneo R; Ouchi T; Horvath CM
J Virol; 2006 Jun; 80(11):5644-50. PubMed ID: 16699046
[TBL] [Abstract][Full Text] [Related]
12. The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.
Le Clorennec C; Lazrek Y; Dubreuil O; Larbouret C; Poul MA; Mondon P; Melino G; Pèlegrin A; Chardès T
Oncotarget; 2016 Jun; 7(24):37013-37029. PubMed ID: 27203743
[TBL] [Abstract][Full Text] [Related]
13. The ubiquitin E3 ligase MDM2 induces chemoresistance in colorectal cancer by degradation of ING3.
Zhang L; Zhu D; Jiang J; Min Z; Fa Z
Carcinogenesis; 2023 Oct; 44(7):562-575. PubMed ID: 37279970
[TBL] [Abstract][Full Text] [Related]
14. TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression.
Zhang Y; Huang Z; Li K; Xie G; Feng Y; Wang Z; Li N; Liu R; Ding Y; Wang J; Yang J; Jia Z
J Exp Clin Cancer Res; 2024 Jan; 43(1):16. PubMed ID: 38200609
[TBL] [Abstract][Full Text] [Related]
15. An E3 ligase TRIM1 promotes colorectal cancer progression via K63-linked ubiquitination and activation of HIF1α.
Shi L; Fang X; Du L; Yang J; Xue J; Yue X; Xie D; Hui Y; Meng K
Oncogenesis; 2024 May; 13(1):16. PubMed ID: 38769340
[TBL] [Abstract][Full Text] [Related]
16. MDM2 accelerated renal senescence via ubiquitination and degradation of HDAC1.
Xiang HL; Yuan Q; Zeng JY; Xu ZY; Zhang HZ; Huang J; Song AN; Xiong J; Zhang C
Acta Pharmacol Sin; 2024 May; ():. PubMed ID: 38760541
[TBL] [Abstract][Full Text] [Related]
17. Retraction notice to "MicroRNA-498 disturbs the occurrence and aggression of colon cancer through targeting MDM2 to mediate PPARγ ubiquitination" [Life Sci. 277 (2021) 119225].
Liu C; Zhang W; Xing W; Li H; Si T; Mu H
Life Sci; 2023 Apr; 319():121428. PubMed ID: 36804898
[No Abstract] [Full Text] [Related]
18. Corrigendum: Differential requirements for MDM2 E3 activity during embryogenesis and in adult mice.
Humpton TJ; Nomura K; Weber J; Magnussen HM; Hock AK; Nixon C; Dhayade S; Stevenson D; Huang DT; Strathdee D; Blyth K; Vousden KH
Genes Dev; 2021 Jul; 35(13-14):1071. PubMed ID: 34210805
[No Abstract] [Full Text] [Related]
19. The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression.
Amelio I; Melino G
Trends Biochem Sci; 2015 Aug; 40(8):425-34. PubMed ID: 26032560
[TBL] [Abstract][Full Text] [Related]
20. Np9, a cellular protein of retroviral ancestry restricted to human, chimpanzee and gorilla, binds and regulates ubiquitin ligase MDM2.
Heyne K; Kölsch K; Bruand M; Kremmer E; Grässer FA; Mayer J; Roemer K
Cell Cycle; 2015; 14(16):2619-33. PubMed ID: 26103464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
